ORIGINAL ARTICLE
Pan-p63 but not ΔNp63 (p40) expression in undifferentiated carcinoma of the pancreas
1
Department of Pathomorphology and Molecular Diagnostics, Medical University of Silesia, Katowice, Poland
Submission date: 2019-06-04
Final revision date: 2019-09-22
Acceptance date: 2019-09-30
Publication date: 2020-07-22
Pol J Pathol 2020;71(2):155-172
KEYWORDS
TOPICS
ABSTRACT
Undifferentiated carcinoma of the pancreas (UC) is a carcinoma without a definitive direction of differentiation. Tumour protein p63 is a regulator of squamous phenotype, which may also be engaged in tumour development. N-terminal isoforms of p63 are TAp63 and ΔNp63. Pan-p63 antibodies are able to detect both isoforms, whereas p40 antibodies recognise the ΔNp63 isoform only. The aim of the study was to describe pan-p63/p40 immunohistochemical expression patterns in pancreatic neoplasms: UC, ductal adenocarcinomas, neuroendocrine tumours, neuroendocrine carcinomas, serous cystic neoplasms, and solid pseudopapillary neoplasms. DAK-p63 and BC28 antibodies were used for pan-p63 and p40 detection, respectively. Moderate-to-strong pan-p63 was found in anaplastic (pleomorphic giant cell) UC (n = 4), sarcomatoid UC (n = 2), UC with osteoclast-like giant cells (n = 3), and ductal carcinomas with partial squamous differentiation. Weak and focal pan-p63 expression was found in monomorphic UC (n = 3) and in the majority of neuroendocrine carcinomas (6/7 cases). Pan-p63 expression was infrequent in ductal carcinomas without squamous differentiation and in neuroendocrine tumours. Serous cystic and solid pseudopapillary neoplasms were pan-p63-negative. Ductal carcinomas with partial squamous differentiation were the only tumours with evident p40 expression. Pan-p63(+)/p40(–) immunohistochemical status may be supportive for UC diagnosis. The pan-p63 expression was not equivalent to squamous differentiation in pancreatic neoplasia.
REFERENCES (116)
1.
Hruban RH, Adsay NV, Esposito I, et al. Pancreatic ductal adenocarcinoma. In: WHO classification of tumours. Digestive system tumours. WHO classification of tumours Editorial Board (eds). 5th ed. International Agency for Research on Cancer, Lyon 2019; 322-332.
2.
Fukushima N, Hruban RH, Kato Y, et al. Ductal adenocarcinoma variants and mixed neoplasms. In: WHO classification of tumours of the digestive system. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). 4th ed. International Agency for Research on Cancer, Lyon 2010; 292-295.
3.
Hruban RH, Pitman MB, Klimstra DS. AFIP Atlas of Tumor Pathology. Tumors of the pancreas. Fourth series. American Registry of Pathology, Washington 2007.
4.
Morohoshi T, Held G, Klöppel G. Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases. Histopathology 1983; 7: 645-661.
5.
Alguacil-Garcia A, Weiland LH. The histologic spectrum, prognosis, and histogenesis of the sarcomatoid carcinoma of the pancreas. Cancer 1977; 39: 1181-1189.
6.
Agaimy A, Haller F, Frohnauer J, et al. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. Mod Pathol 2015; 28: 248-260.
7.
Solcia E, Capella C, Klöppel G. Atlas of Tumor Pathology. Tumors of the pancreas. Third series. Armed Forces Institute of Pathology, Washington 1995.
8.
Paal E, Thompson LD, Frommelt RA, et al. A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann Diagn Pathol 2001; 5: 129-140.
9.
Tschang TP, Garza-Garza R, Kissane JM. Pleomorphic carcinoma of the pancreas: an analysis of 15 cases. Cancer 1977; 3: 2114-2126.
10.
Luchini C, Pea A, Lionheart G, et al. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. J Pathol 2017; 243: 148-154.
11.
Molberg KH, Heffess C, Delgado R, et al. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region. Cancer 1998; 82: 1279-1287.
12.
Muraki T, Reid MD, Basturk O, et al. Undifferentiated carcinoma with osteoclastic giant cells of the pancreas: clinicopathologic analysis of 38 cases highlights a more protracted clinical course than currently appreciated. Am J Surg Pathol 2016; 40: 1203-1216.
13.
Krasinskas AM, Moser AJ, Saka B, et al. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Mod Pathol 2013; 26: 1346-1354.
14.
Voong KR, Davison J, Pawlik TM, et al. Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol 2010; 41: 113-122.
15.
Kardon DE, Thompson LD, Przygodzki RM, et al. Adenosquamous carcinoma of the pancreas: a clinicopathologic series of 25 cases. Mod Pathol 2001; 14: 443-451.
16.
Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-1813.
17.
Schmale H, Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene 1997; 15: 1363-1367.
18.
Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316.
19.
Soares E, Zhou H. Master regulatory role of p63 in epidermal development and disease. Cell Mol Life Sci 2018; 75: 1179-1190.
20.
Petitjean A, Ruptier C, Tribollet V, et al. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Carcinogenesis 2008; 29: 273-281.
21.
Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer 2013; 13: 136-143.
22.
Chen Y, Peng Y, Fan S, et al. A double dealing tale of p63: an oncogene or a tumor suppressor. Cell Mol Life Sci 2018; 75: 965-973.
23.
Bergholz J, Xiao ZX. Role of p63 in development, tumorigenesis and cancer progression. Cancer Microenviron 2012; 5: 311-322.
24.
Wu G, Nomoto S, Hoque MO, et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 2003; 63: 2351-2357.
25.
Gatti V, Fierro C, Annicchiarico-Petruzzelli M, et al. ΔNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment. Mol Oncol 2019; 13: 981-1001.
26.
Lau CP, Ng PK, Li MS, et al. p63 regulates cell proliferation and cell cycle progression associated genes in stromal cells of giant cell tumor of the bone. Int J Oncol 2013; 42: 437-443.
27.
Crook T, Nicholls JM, Brooks L, et al. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000; 19: 3439-3444.
28.
Sbisà E, Mastropasqua G, Lefkimmiatis K, et al. Connecting p63 to cellular proliferation: the example of the adenosine deaminase target gene. Cell Cycle 2006; 5: 205-212.
29.
Rocco JW, Leong CO, Kuperwasser N, et al. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45-56.
30.
Somerville TDD, Xu Y, Miyabayashi K, et al. TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma. Cell Rep 2018; 25: 1741-1755.e7.
31.
Su X, Chakravarti D, Cho MS, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467: 986-990.
32.
Malaguarnera R, Mandarino A, Mazzon E, et al. The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer 2005; 12: 953-971.
33.
Keyes WM, Pecoraro M, Aranda V, et al. ΔNp63α is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2011; 8: 164-176.
34.
Guo X, Keyes WM, Papazoglu C, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 2009; 11: 1451-1457.
35.
Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012; 25: 405-415.
36.
Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002; 198: 417-427.
37.
Tan EH, Morton JP, Timpson P, et al. Functions of TAp63 and p53 in restraining the development of metastatic cancer. Oncogene 2014; 33: 3325-3333.
38.
Sethi I, Romano RA, Gluck C, et al. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues. BMC Genomics 2015; 16: 584.
39.
Coates PJ, Nenutil R, Holcakova J, et al. p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. Virchows Arch 2018; 472: 351-359.
40.
Park S, Lee S, Kim J, et al. ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis. PLoS One 2019; 14: e0214867.
41.
Su X, Paris M, Gi YJ, et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 2009; 5: 64-75.
42.
Luo G, Xia X, Wang X, et al. miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer. Exp Cell Res 2018; 369: 120-128.
43.
Sugimoto H, Nakamura M, Yoda H, et al. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discov 2015; 1: 15010.
44.
Gunaratne PH, Pan Y, Rao AK, et al. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors. Cancer 2019; 125: 2409-2422.
45.
Uchida K, Ross H, Lotan T, et al. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Hum Pathol 2015; 46: 384-389.
46.
Tacha D, Bremer R, Haas T, et al. An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) antibody in lung, bladder, skin, breast, prostate, and head and neck cancers. Arch Pathol Lab Med 2014; 138: 1358-1364.
47.
Sailer V, Stephan C, Wernert N, et al. Comparison of p40 (ΔNp63) and p63 expression in prostate tissues - which one is the superior diagnostic marker for basal cells? Histopathology 2013; 63: 50-56.
48.
Khazai L, Agosto-Arroyo E, Rosa M. P40 immunostain does not outperform p63 as a myoepithelial cell marker in the daily practice of breast pathology. Appl Immunohistochem Mol Morphol 2018; 26: 599-604.
49.
Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001; 116: 823-830.
50.
p63 antibody. DAK-p63. Product specification sheet provided by the manufacturer (Dako/Agilent) URL: https://www.agilent.com/en/pro... Assessed November 21, 2018.
51.
Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63: 7113-7121.
52.
Liszka £. Ductal adenocarcinoma of the pancreas usually retained SMAD4 and p53 protein status as well as expression of epithelial-to-mesenchymal transition markers and cell cycle regulators at the stage of liver metastasis. Pol J Pathol 2014; 65: 100-112.
53.
Paj¹k J, Liszka £, Mrowiec S, et al. Serous neoplasms of the pancreas constitute a continuous spectrum of morphological patterns rather than distinct clinico-pathological variants. A study of 40 cases. Pol J Pathol 2011; 62: 206-217.
54.
Liszka £. Alpha-methylacyl-CoA racemase is expressed in a majority of pancreatic neoplasms of neuroendocrine, acinar, and solid pseudopapillary differentiation. Pathology 2015; 47: 466-468.
55.
Liszka L, Mrowiec S, Paj¹k J, et al. Limited usefulness of histopathological features in identification of a clinically aggressive solid-pseudopapillary neoplasm of the pancreas. Pol J Pathol 2014; 65: 182-193.
56.
Klöppel G, Couvelard A, Hruban RH, et al. Neoplasms of the neuroendocrine pancreas. Introduction. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds.). WHO classification of tumours of endocrine organs. 4th ed. International Agency for Research on Cancer, Lyon 2017; 211-214.
57.
Chilosi M, Zamò A, Brighenti A, et al. Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 2003; 443: 175-183.
58.
Wang X, Boddicker RL, Dasari S, et al. Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. Hum Pathol 2017; 64: 19-27.
59.
Pruneri G, Fabris S, Dell’Orto P, et al. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol 2005; 206: 337-345.
60.
Robson A, Shukur Z, Ally M, et al. Immunocytochemical p63 expression discriminates between primary cutaneous follicle centre cell and diffuse large B cell lymphoma-leg type, and is of the TAp63 isoform. Histopathology 2016; 69: 11-19.
61.
Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347: 1260419.
62.
Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 2017; 32: 185-203.e13.
64.
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531: 47-52.
65.
R2: genomic analysis and visualization platform. URL: https://hgserver1.amc.nl/cgi-b... Assessed May 18, 2019.
66.
Knijn N, Nagtegaal ID. Guidelines for reporting histopathology studies. J Clin Pathol 2015; 68: 173-174.
67.
p40 antibody. BC28. Product specification sheet provided by the manufacturer (Abcam). URL: https://www.abcam.com/p40-delt... Assessed: April 20, 2019.
70.
Nekulova M, Holcakova J, Nenutil R, et al. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry. Virchows Arch 2013; 463: 415-425.
71.
Basturk O, Khanani F, Sarkar F, et al. DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod Pathol 2005; 18: 1193-1198.
72.
Genotype - tissue expression (GTEx) data. URL: https://gtexportal.org/home/ge... Assessed May 12, 2019.
73.
Nicolle R, Raffenne J, Paradis V, et al. Prognostic biomarkers in pancreatic cancer: avoiding errata when using the TCGA dataset. Cancers (Basel) 2019; 11: 126.
74.
Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 2015; 47: 1168-1178.
75.
Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500-503.
76.
Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002; 8: 494-501.
77.
Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24: 1348-1359.
78.
Szade J, Majewska HI, ¯aczek AJ, et al. High-grade non-small cell lung carcinoma: a comparative analysis of the phenotypic profile in small biopsies with the corresponding postoperative material. Pol J Pathol 2019; 70: 100-108.
79.
Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol 2011; 6: 1190-1199.
80.
Tatsumori T, Tsuta K, Masai K, et al. p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2. Appl Immunohistochem Mol Morphol 2014; 22: 377-382.
81.
Ishida H, Kasajima A, Kamei T, et al. SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesis. Mod Pathol 2017; 30: 660-671.
82.
Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, Burstein DE. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 2002; 33: 921-926.
83.
Affandi KA, Tizen NMS, Mustangin M, et al. p40 immunohistochemistry is an excellent marker in primary lung squamous cell carcinoma. J Pathol Transl Med 2018; 52: 283-289.
84.
Brody JR, Costantino CL, Potoczek M, et al. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol 2009; 22: 651-659.
85.
Simtniece Z, Vanags A, Strumfa I, et al. Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms. Pol J Pathol 2015; 66: 176-194.
86.
Khatri I, Ganguly K, Sharma S, et al. Systems biology approach to identify novel genomic determinants for pancreatic cancer pathogenesis. Sci Rep 2019; 9: 123.
87.
Borazanci E, Millis SZ, Korn R, et al. Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review. World J Gastrointest Oncol 2015; 7: 132-140.
88.
Wartenberg M, Cibin S, Zlobec I, et al. Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance. Clin Cancer Res 2018; 24: 4444-4454.
89.
Mangiulli M, Valletti A, Caratozzolo MF, et al. Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res 2009; 37: 6092-6104.
90.
Kane JR, Laskin WB, Matkowskyj KA, et al. Sarcomatoid (spindle cell) carcinoma of the pancreas: A case report and review of the literature. Oncol Lett 2014; 7: 245-249.
91.
Sekulic M, Gilles S, Amin K, et al. Undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: a series of 5 cases with clinicopathologic correlation and cytomorphologic characterization. J Am Soc Cytopathol 2016; 5: 321-330.
92.
Maksymov V, Khalifa MA, Bussey A, et al. Undifferentiated (anaplastic) carcinoma of the pancreas with osteoclast-like giant cells showing various degree of pancreas duct involvement. A case report and literature review. JOP 2011; 12: 170-176.
93.
Aubry MC, Roden A, Murphy SJ, et al. Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma. Mod Pathol 2015; 28: 359-366.
94.
Campbell JD, Yau C, Bowlby R, et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep 2018; 23: 194-212.e6.
95.
Mueller S, Engleitner T, Maresch R, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 2018; 554: 62-68.
96.
Bishop JA, Montgomery EA, Westra WH. Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes. Am J Surg Pathol 2014; 38: 257-264.
97.
Jo VY, Fletcher CD. p63 immunohistochemical staining is limited in soft tissue tumors. Am J Clin Pathol 2011; 136: 762-766.
98.
Lewis JS, Ritter JH, El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder – p63, MOC-31, and TTF-1. Mod Pathol 2005; 18: 1471-1481.
99.
Ishida K, Yamashita R, Osakabe M, et al. Expression of epithelial-mesenchymal transition proteins in pancreatic anaplastic (undifferentiated) carcinoma. Pancreas 2019; 48: 36-42.
100.
Sano M, Homma T, Hayashi E, et al. Clinicopathological characteristics of anaplastic carcinoma of the pancreas with rhabdoid features. Virchows Arch 2014; 465: 531-538.
101.
Winter JM, Ting AH, Vilardell F, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008; 14: 412-418.
102.
Lehrke HD, Graham RP, McWilliams RR, et al. Undifferentiated pancreatic carcinomas display enrichment for frequency and extent of PD-L1 expression by tumor cells. Am J Clin Pathol 2017; 148: 441-449.
103.
Rosai J. Carcinoma of pancreas simulating giant cell tumor of bone. Electron-microscopic evidence of its acinar cell origin. Cancer 1968; 22: 333-344.
104.
Dickson BC, Li SQ, Wunder JS, et al. Giant cell tumor of bone express p63. Mod Pathol 2008; 21: 369-375.
105.
Lee CH, Espinosa I, Jensen KC, et al. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod Pathol 2008; 21: 531-539.
106.
Yanagisawa M, Kakizaki H, Okada K, et al. p63 as a prognostic marker for giant cell tumor of bone. Ups J Med Sci 2013; 118: 23-28.
107.
Ha Lan TT, Chen SJ, Arps DP, et al. Expression of the p40 isoform of p63 has high specificity for cutaneous sarcomatoid squamous cell carcinoma. Cutan Pathol 2014; 41: 831-838.
108.
Weissferdt A, Kalhor N, Correa AM, et al. “Sarcomatoid” carcinomas of the lung: a clinicopathological study of 86 cases with a new perspective on tumor classification. Hum Pathol 2017; 63: 14-26.
109.
Masai K, Tsuta K, Kawago M, et al. Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol 2013; 21: 292-297.
110.
Ferronika P, Triningsih FX, Ghozali A, et al. p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression. Asian Pac J Cancer Prev 2012; 13: 1943-1948.
111.
Hsiao YH, Su YA, Tsai HD, et al. Increased invasiveness and aggressiveness in breast epithelia with cytoplasmic p63 expression. Int J Biol Sci 2010; 6: 428-442.
112.
Hiroshima K, Iyoda A, Shida T, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006; 19: 1358-1368.
113.
McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol 2010; 34: 525-532.
114.
Serrano MF, El-Mofty SK, Gnepp DR, Lewis JS Jr. Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck. Hum Pathol 2008; 39: 591-598.
115.
Asioli S, Righi A, Volante M, et al. p63 expression as a new prognostic marker in Merkel cell carcinoma. Cancer 2007; 110: 640-647.
116.
Nakajima N, Yoshizawa A, Moriyoshi K, et al. P40 expression in small cell lung cancer: The presence of p40-positive cells does not always indicate squamous differentiation. Thorac Cancer 2019; 10: 1188-1192.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
